The acquisition of the St. Gallen laboratory Vifor by CSL may not be finalized by the end of June. In a statement released on Thursday, the Swiss Stock Exchange-listed company said some regulatory approvals were still pending.
The Australian group had said the day before that it thought it would be able to finalize the transaction before the end of the semester. ‘Delays in the regulatory approval process are not unusual,’ assures Vifor management.
Both companies continue to ‘work closely with the respective remaining competition authorities in their review of the tender offer’ and are committed to providing an update to shareholders and investors’ as soon as the timetable becomes clearer.
Exact dates for finalization and settlement will be communicated once all regulatory green lights have been obtained. CSL says it ‘remains confident’ about the completion of its acquisition of Vifor Pharma.
In March, the Australian group welcomed the “success” of its takeover of the Saint-Gallen laboratory. Once the transaction is finalized, the Vifor share will be subject to a request for delisting on the Swiss Stock Exchange.
CSL had announced in mid-December its intention to buy Vifor Pharma for 179.25 dollars per share from the Swiss group, representing a total value of 11 billion francs.
/ATS